TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Börresen, A L
Ogmundsdottir, H M
Eyfjord, J E
MetadataShow full item record
CitationEur. J. Cancer. 1995, 31A(11):1856-61
AbstractAbnormalities in the TP53 tumour suppressor gene were evaluated in 106 unselected breast carcinomas and compared to clinical outcome of the disease. Tumours were screened for p53 abnormalities using immunohistochemical staining and polymerase chain reaction-constant denaturant gel electrophoresis (PCR-CDGE) analysis, followed by PCR and direct sequencing. Allelic loss at the TP53 locus was determined with polymorphic markers by comparing normal and tumour DNA. For approximately half of the patients, abnormal p53 protein expression in serum was determined by an ELISA assay. p53 abnormalities, detected as mutations and/or nuclear staining, were found in 37.6 (38/101) of cases. Nuclear staining for p53 protein could be identified in 33.7% of the tumours. Mutations in exons 5-8 were detected in 18.9% of the tumours, and an association was found between mutations and nuclear staining. Allelic loss in the TP53 region on 17p was more frequent in tumours showing changes in the TP53 gene (72.7%) compared to tumours with no mutation (45.8%). Serum levels of p53 antibodies showed no association with either TP53 mutations or nuclear staining. Women with TP53 mutations in their tumours had an elevated risk of dying during the study period (RR (relative risk) = 3.4, P = 0.014). The effects of p53 positive staining were similar (RR = 3.2, P = 0.013). Considering all abnormalities, mutation and/or staining, the relative risk of dying from breast cancer was 3.5 (P = 0.008).
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis.
- Authors: Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson JG, Ogmundsdottir HM, Eyfjörd JE
- Issue date: 1997 Feb
- Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas.
- Authors: Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, Nesland JM, Børresen AL
- Issue date: 1993 Oct
- TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
- Authors: Gretarsdottir S, Tryggvadottir L, Jonasson JG, Sigurdsson H, Olafsdottir K, Agnarsson BA, Ogmundsdottir H, Eyfjörd JE
- Issue date: 1996 Aug
- TP53 abnormalities and genetic instability in breast cancer.
- Authors: Eyfjörd JE, Thorlacius S, Valgardsdottir R, Gretarsdottir S, Steinarsdottir M, Anamthawat-Jonsson K
- Issue date: 1995
- Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
- Authors: Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Børresen AL, Cornelisse CJ, Devilee P
- Issue date: 1994 Aug 1